Last reviewed · How we verify

Jennifer Gassman, PhD — Portfolio Competitive Intelligence Brief

Jennifer Gassman, PhD pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Lower Dose Sodium Bicarbonate Lower Dose Sodium Bicarbonate phase 3 Alkalizing agent Nephrology
Higher Dose Sodium Bicarbonate Higher Dose Sodium Bicarbonate phase 3 Alkalinizing agent Nephrology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Hospital General "Dr. Miguel Silva" de Morelia · 1 shared drug class
  2. Nantes University Hospital · 1 shared drug class
  3. Sheba Medical Center · 1 shared drug class
  4. The Western Pennsylvania Hospital · 1 shared drug class
  5. University of Baghdad · 1 shared drug class
  6. VA Greater Los Angeles Healthcare System · 1 shared drug class
  7. VA Office of Research and Development · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jennifer Gassman, PhD:

Cite this brief

Drug Landscape (2026). Jennifer Gassman, PhD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jennifer-gassman-phd. Accessed 2026-05-17.

Related